China · Delayed Price · Currency is CNY Bide Pharmatech Statistics
Total Valuation
Bide Pharmatech has a market cap or net worth of CNY 5.50 billion. The enterprise value is 4.51 billion.
| Market Cap | 5.50B |
| Enterprise Value | 4.51B |
Important Dates
The last earnings date was Friday, October 30, 2026.
| Earnings Date | Oct 30, 2026 |
| Ex-Dividend Date | Jun 10, 2026 |
Share Statistics
Bide Pharmatech has 86.15 million shares outstanding. The number of shares has decreased by -0.83% in one year.
| Current Share Class | 86.15M |
| Shares Outstanding | 86.15M |
| Shares Change (YoY) | -0.83% |
| Shares Change (QoQ) | -0.26% |
| Owned by Insiders (%) | 51.72% |
| Owned by Institutions (%) | 15.74% |
| Float | 33.12M |
Valuation Ratios
The trailing PE ratio is 28.32.
| PE Ratio | 28.32 |
| Forward PE | n/a |
| PS Ratio | 4.15 |
| PB Ratio | 2.68 |
| P/TBV Ratio | 2.70 |
| P/FCF Ratio | 31.54 |
| P/OCF Ratio | 28.22 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 16.45, with an EV/FCF ratio of 26.13.
| EV / Earnings | 24.50 |
| EV / Sales | 3.44 |
| EV / EBITDA | 16.45 |
| EV / EBIT | 18.68 |
| EV / FCF | 26.13 |
Financial Position
The company has a current ratio of 7.72, with a Debt / Equity ratio of 0.06.
| Current Ratio | 7.72 |
| Quick Ratio | 4.62 |
| Debt / Equity | 0.06 |
| Debt / EBITDA | 0.45 |
| Debt / FCF | 0.71 |
| Interest Coverage | 218.17 |
Financial Efficiency
Return on equity (ROE) is 9.42% and return on invested capital (ROIC) is 17.62%.
| Return on Equity (ROE) | 9.42% |
| Return on Assets (ROA) | 6.24% |
| Return on Invested Capital (ROIC) | 17.62% |
| Return on Capital Employed (ROCE) | 11.31% |
| Weighted Average Cost of Capital (WACC) | 7.32% |
| Revenue Per Employee | 1.90M |
| Profits Per Employee | 266,949 |
| Employee Count | 734 |
| Asset Turnover | 0.54 |
| Inventory Turnover | 0.82 |
Taxes
In the past 12 months, Bide Pharmatech has paid 48.02 million in taxes.
| Income Tax | 48.02M |
| Effective Tax Rate | 19.68% |
Stock Price Statistics
The stock price has decreased by -14.75% in the last 52 weeks. The beta is 0.58, so Bide Pharmatech's price volatility has been lower than the market average.
| Beta (5Y) | 0.58 |
| 52-Week Price Change | -14.75% |
| 50-Day Moving Average | 64.70 |
| 200-Day Moving Average | 59.28 |
| Relative Strength Index (RSI) | 48.20 |
| Average Volume (20 Days) | 4,596,581 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Bide Pharmatech had revenue of CNY 1.40 billion and earned 195.94 million in profits. Earnings per share was 2.26.
| Revenue | 1.40B |
| Gross Profit | 638.30M |
| Operating Income | 256.88M |
| Pretax Income | 243.96M |
| Net Income | 195.94M |
| EBITDA | 273.40M |
| EBIT | 256.88M |
| Earnings Per Share (EPS) | 2.26 |
Balance Sheet
The company has 1.12 billion in cash and 130.15 million in debt, with a net cash position of 993.29 million or 11.53 per share.
| Cash & Cash Equivalents | 1.12B |
| Total Debt | 130.15M |
| Net Cash | 993.29M |
| Net Cash Per Share | 11.53 |
| Equity (Book Value) | 2.16B |
| Book Value Per Share | 24.91 |
| Working Capital | 2.08B |
Cash Flow
In the last 12 months, operating cash flow was 205.31 million and capital expenditures -21.62 million, giving a free cash flow of 183.69 million.
| Operating Cash Flow | 205.31M |
| Capital Expenditures | -21.62M |
| Depreciation & Amortization | 16.52M |
| Net Borrowing | -121.19M |
| Free Cash Flow | 183.69M |
| FCF Per Share | 2.13 |
Margins
Gross margin is 45.72%, with operating and profit margins of 18.40% and 14.04%.
| Gross Margin | 45.72% |
| Operating Margin | 18.40% |
| Pretax Margin | 17.48% |
| Profit Margin | 14.04% |
| EBITDA Margin | 19.59% |
| EBIT Margin | 18.40% |
| FCF Margin | 13.16% |
Dividends & Yields
This stock pays an annual dividend of 1.16, which amounts to a dividend yield of 1.82%.
| Dividend Per Share | 1.16 |
| Dividend Yield | 1.82% |
| Dividend Growth (YoY) | 28.89% |
| Years of Dividend Growth | n/a |
| Payout Ratio | 52.20% |
| FCF Payout Ratio | 54.41% |
| Buyback Yield | 0.83% |
| Shareholder Yield | 2.56% |
| Earnings Yield | 3.53% |
| FCF Yield | 3.17% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside | |
| Graham Formula Value | |
| Graham Formula Upside |
Stock Splits
The last stock split was on May 25, 2023. It was a forward split with a ratio of 1.4.
| Last Split Date | May 25, 2023 |
| Split Type | Forward |
| Split Ratio | 1.4 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 7 |